Two Year Sustained Cognitive Benefits of Hydromethylthionine Mesylate (HMTM) Indicated by TauRx's LUCIDITY Trial
View the full release here: https://www.businesswire.com/news/home/20240307066794/en/
- View the full release here: https://www.businesswire.com/news/home/20240307066794/en/
New 24-month data show sustained benefits across the disease spectrum from early to moderate dementia. - Analyses comparing the study participants to closely matched real world data and meta-analytical controls, showed significantly reduced disease progression in participants in the LUCIDITY trial.
- In the early disease subgroup there was a significant reduction in transition to the dementia stage of AD.
- Its secondary pharmacological action is symptomatic through increasing acetylcholine levels in parts of the brain essential for memory functions.